ScreenerHero

CGEMCullinan Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · cullinantherapeutics.com
21.68USD-3.73%Mkt Cap: 1.40B $P/E: —

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.40B $
Enterprise Value1.04B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-219.88M $
Revenue/Share—
Last Price21.68 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees109
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.89
PEG—
EV/EBITDA-4.71
EV/Revenue—
P/S—
P/B4.28
EPS (TTM)-2.95
EPS (Forward)-2.71
52W Range
5.68095% of range22.54
52W High22.54 USD
52W Low5.680 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-53.80%
ROA-49.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-175.75M $
CapEx (TTM)49.00K $
FCF Margin—
FCF Yield-6.40%
Net Debt-332.47M $
Net Debt/EBITDA1.50
Balance Sheet
Debt/Equity0.01
Current Ratio8.42
Quick Ratio8.29
Book Value/Sh5.000 USD
Cash/Share5.198 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)32.36 USD
Upside (mean)+49.3%
Target Range23.00 USD – 42.00 USD
$23.00+49.3% to mean$42.00
# Analysts11
Ownership
Shares Out.64.35M
Float48.08M
Insiders0.43%
Institutions112.56%
Short Interest
Short Ratio16.9d
Short % Float22.19%
Short % Out.15.93%
Shares Short10.25M
Short (prev mo.)10.60M
Technical
SMA 5017.57 (+23.4%)
SMA 20013.83 (+56.7%)
Beta-0.02
S&P 52W Chg18.16%
Avg Vol (30d)612.62K
Avg Vol (10d)797.69K
Technical Indicators
RSI (14)70.1
MACD1.1194
MACD Signal0.7097
MACD Hist.+0.4097
BB Upper21.98 USD
BB Middle18.49 USD
BB Lower15.01 USD
BB Width37.72%
ATR (14)1.195 USD
Vol Ratio (20d)1.18x